Stemline Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference
01 mai 2017 07h00 HE
|
Stemline Therapeutics
NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
Stemline Therapeutics Announces Completion of Enrollment in Stage 3 of the SL-401 Pivotal Trial in BPDCN
23 mars 2017 07h00 HE
|
Stemline Therapeutics
NEW YORK, March 23, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
Stemline Therapeutics Reports Fourth Quarter 2016 Financial Results
16 mars 2017 19h25 HE
|
Stemline Therapeutics
NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
Stemline Therapeutics to Present at the 29th Annual ROTH Conference
10 mars 2017 07h00 HE
|
Stemline Therapeutics
NEW YORK, March 10, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
Stemline Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference
02 mars 2017 11h31 HE
|
Stemline Therapeutics
NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
Stemline Therapeutics Provides Update on Clinical Programs
21 févr. 2017 07h00 HE
|
Stemline Therapeutics
NEW YORK, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
Stemline Therapeutics Provides Update on Pivotal BPDCN Trial
02 févr. 2017 15h24 HE
|
Stemline Therapeutics
NEW YORK, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, provides an update on its...
Stemline Therapeutics Prices $45 Million Public Offering of Common Stock
20 janv. 2017 09h00 HE
|
Stemline Therapeutics
NEW YORK, Jan. 20, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the pricing...
Stemline Therapeutics Announces Proposed Public Offering of Common Stock
19 janv. 2017 16h03 HE
|
Stemline Therapeutics
NEW YORK, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced that it...
Stemline Therapeutics Announces Date Change for the Company’s Presentation at the 35th Annual J.P. Morgan Healthcare Conference
09 janv. 2017 17h15 HE
|
Stemline Therapeutics
NEW YORK, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline’s CEO, will now present at the 35th Annual J.P. Morgan...